176 related articles for article (PubMed ID: 37344468)
21. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
[TBL] [Abstract][Full Text] [Related]
22. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
23. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
24. Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female.
Wyvekens N; Anderson WJ; Kim YX; Carter M; Hirsch MS
Int J Surg Pathol; 2022 Apr; 30(2):184-189. PubMed ID: 34180725
[TBL] [Abstract][Full Text] [Related]
25. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
[TBL] [Abstract][Full Text] [Related]
26. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
[TBL] [Abstract][Full Text] [Related]
27. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
28. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
[TBL] [Abstract][Full Text] [Related]
29. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
[TBL] [Abstract][Full Text] [Related]
31. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
[TBL] [Abstract][Full Text] [Related]
32. Cascade Fumarate Hydratase mutation screening allows early detection of kidney tumour: a case report.
Chan MMY; Barnicoat A; Mumtaz F; Aitchison M; Side L; Brittain H; Bates AWH; Gale DP
BMC Med Genet; 2017 Jul; 18(1):79. PubMed ID: 28747166
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
[TBL] [Abstract][Full Text] [Related]
34. Fumarate Hydratase is a Novel Gene for Familial Non-Medullary Thyroid Cancer.
Alzahrani AS; Alswailem M; Alghamdi B; Al-Hindi H
J Clin Endocrinol Metab; 2022 Aug; 107(9):2539-2544. PubMed ID: 35751867
[TBL] [Abstract][Full Text] [Related]
35. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.
Zhang L; Walsh MF; Jairam S; Mandelker D; Zhong Y; Kemel Y; Chen YB; Musheyev D; Zehir A; Jayakumaran G; Brzostowski E; Birsoy O; Yang C; Li Y; Somar J; DeLair D; Pradhan N; Berger MF; Cadoo K; Carlo MI; Robson ME; Stadler ZK; Iacobuzio-Donahue CA; Joseph V; Offit K
Hum Mutat; 2020 Jan; 41(1):103-109. PubMed ID: 31444830
[TBL] [Abstract][Full Text] [Related]
36. A patient with very early onset FH-deficient renal cell carcinoma diagnosed at age seven.
Taniguchi R; Muramatsu H; Okuno Y; Yoshida T; Wakamatsu M; Hamada M; Shirota C; Sumida W; Hinoki A; Tainaka T; Gotoh Y; Tsuzuki T; Tanaka Y; Kojima S; Uchida H; Takahashi Y
Fam Cancer; 2022 Jul; 21(3):337-341. PubMed ID: 34156580
[TBL] [Abstract][Full Text] [Related]
37. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
[TBL] [Abstract][Full Text] [Related]
38. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
[TBL] [Abstract][Full Text] [Related]
39. [Hereditary leiomyomatosis syndrome associated with renal cell carcinoma. A case report].
González Ibáñez MV; Ruiz Cabezas L; Moreno Ontalba A; Rubio Fernández A; Mayoral Guisado C; Flores Barranquero M; Díaz Delgado M
Rev Esp Patol; 2021; 54(3):193-196. PubMed ID: 34175032
[TBL] [Abstract][Full Text] [Related]
40. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
